Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17663495 | 0.84 | AAK1 (0.49) | AAK1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17653152 | 0.79 | AAK1 (0.78) | AAK1 | |
| SCHEMBL17653291 | 0.79 | AAK1 (0.42) | AAK1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17653328 | 0.75 | AAK1 (0.43) | AAK1 | |
| SCHEMBL17653147 | 0.75 | AAK1 (0.43) | AAK1 | |
| SCHEMBL17653098 | 0.74 | AAK1 (0.57) | AAK1 | |
| SCHEMBL17653342 | 0.73 | AAK1 (0.47) | AAK1RXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17663448 | 0.73 | AAK1 (0.63) | AAK1 | |
| SCHEMBL17653396 | 0.70 | AAK1 (0.53) | AAK1 | |
| SCHEMBL21004358 | 0.68 | RXFP1 (0.56) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3200797-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | AAK1 1/4885CYP1A2 4763/4885CYP2D6 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.